GlassScriptPhysician profile
Paul C Helfgott
NPI 1316922107
$8,240.25
in general payments reported to CMS, 2019-2025
50 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.49 · 2020: $21.87 · 2021: $354 · 2022: $977 · 2023: $1,696 · 2024: $2,865 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,802.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,374.26 | 2019-2025 | |
| Ucb, INC. | $808.71 | 2022-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $787.70 | 2021-2025 | |
| Lundbeck LLC | $548.05 | 2022-2025 | Vyepti, Rexulti |
| Pfizer INC. | $374.66 | 2023-2025 | |
| Lilly USA, LLC | $370.99 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Argenx US, INC. | $350.59 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Mdd US Operations, LLC | $315.09 | 2022-2025 | Gocovri |
| Eisai INC. | $286.74 | 2023-2025 | |
| Celgene Corporation | $276.06 | 2023-2025 | Zeposia |
| Biogen, INC. | $235.86 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Acadia Pharmaceuticals INC | $222.54 | 2023-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $208.07 | 2023-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $207.90 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $188.21 | 2022-2025 | Austedo Xr, Austedo Xr |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Helfgott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.